Literature DB >> 29145710

Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.

B Musicki1, S Karakus1, W Akakpo1, F H Silva1, J Liu2, H Chen2, B R Zirkin2, A L Burnett1.   

Abstract

Sickle cell disease (SCD)-associated priapism is characterized by decreased nitric oxide (NO) signaling and downregulated phosphodiesterase (PDE)5 protein expression and activity in the penis. Priapism is also associated with testosterone deficiency, but molecular mechanisms underlying testosterone effects in the penis in SCD are not known. Given the critical role of androgens in erection physiology and NO synthase (NOS)/PDE5 expression, we hypothesized that testosterone replacement to eugonadal testosterone levels reduces priapism by reversing impaired endothelial (e)NOS activity and molecular abnormalities involving PDE5. Adult male transgenic Berkeley sickle cell (Sickle) and wild-type (WT) mice were implanted with testosterone pellets, which release 1.2 μg testosterone/day for 21 days, or vehicle. After 21 days, animals underwent erectile function assessment followed by collection of blood for serum testosterone measurements, penes for molecular analysis, and seminal vesicles as testosterone-responsive tissue. Serum testosterone levels were measured by radioimmunoassay; protein expressions of PDE5, α-smooth muscle actin, eNOS and nNOS, and phosphorylation of PDE5 at Ser-92, eNOS at Ser-1177, neuronal (n) NOS at Ser-1412, and Akt at Ser-473 were measured by Western blot in penile tissue. Testosterone treatment reversed downregulated serum testosterone levels and increased (p < 0.05) the weight of seminal vesicles in Sickle mice to levels comparable to that of WT mice, indicating restored testosterone levels in Sickle mice. Testosterone treatment reduced (p < 0.05) prolonged detumescence in Sickle mice and normalized downregulated P-PDE5 (Ser-92), PDE5, P-eNOS (Ser-1177), and P-Akt (Ser-473) protein expressions in the Sickle mouse penis. Testosterone treatment did not affect P-nNOS (Ser-1412), eNOS, nNOS, or α-smooth muscle actin protein expressions in the Sickle mouse penis. In conclusion, in the mouse model of human SCD, increasing testosterone to eugonadal levels reduced priapic activity and reversed impaired Akt/eNOS activity and PDE5 protein expression in the penis.
© 2017 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  Akt; eNOS phosphorylation; nNOS phosphorylation

Mesh:

Substances:

Year:  2017        PMID: 29145710      PMCID: PMC5745275          DOI: 10.1111/andr.12442

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  75 in total

1.  Effect of Testosterone on the Phenotypic Modulation of Corpus Cavernosum Smooth Muscle Cells in a Castrated Rat Model.

Authors:  Luhao Liu; Ermao Li; Futian Li; Lianmin Luo; Shankun Zhao; Ran Kang; Jintai Luo; Zhigang Zhao
Journal:  Urology       Date:  2017-02-15       Impact factor: 2.649

2.  Endothelial regulation of eNOS, PAI-1 and t-PA by testosterone and dihydrotestosterone in vitro and in vivo.

Authors:  L Goglia; V Tosi; A M Sanchez; M I Flamini; X-D Fu; S Zullino; A R Genazzani; T Simoncini
Journal:  Mol Hum Reprod       Date:  2010-06-14       Impact factor: 4.025

3.  The mechanism of low testosterone levels in homozygous sickle-cell disease.

Authors:  O Parshad; M C Stevens; M A Preece; P W Thomas; G R Serjeant
Journal:  West Indian Med J       Date:  1994-03       Impact factor: 0.171

4.  Testicular dysfunction in men with sickle cell disease.

Authors:  D N Osegbe; O O Akinyanju
Journal:  Postgrad Med J       Date:  1987-02       Impact factor: 2.401

5.  Priapism in teenage boys following depot testosterone.

Authors:  James F Donaldson; Nikki Davis; Justin H Davies; Roland W Rees; Henrik A Steinbrecher
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

6.  Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells.

Authors:  Shibo Fu; Moses Tarndie Tar; Arnold Melman; Kelvin Paul Davies
Journal:  FASEB J       Date:  2014-05-06       Impact factor: 5.191

7.  Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa.

Authors:  Annamaria Morelli; Sandra Filippi; Rosa Mancina; Michaela Luconi; Linda Vignozzi; Mirca Marini; Claudio Orlando; Gabriella Barbara Vannelli; Antonio Aversa; Alessandro Natali; Gianni Forti; Mauro Giorgi; Emmanuele A Jannini; Fabrizio Ledda; Mario Maggi
Journal:  Endocrinology       Date:  2004-02-05       Impact factor: 4.736

Review 8.  Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.

Authors:  Arthur L Burnett
Journal:  J Androl       Date:  2007-10-17

9.  Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation.

Authors:  Cécile Brachet; Claudine Heinrichs; Sylvie Tenoutasse; Christine Devalck; Nadira Azzi; Alina Ferster
Journal:  J Pediatr Hematol Oncol       Date:  2007-07       Impact factor: 1.289

Review 10.  Androgen actions on endothelium functions and cardiovascular diseases.

Authors:  Jing-Jing Cai; Juan Wen; Wei-Hong Jiang; Jian Lin; Yuan Hong; Yuan-Shan Zhu
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

View more
  9 in total

1.  Resolution of Acute Priapism in Two Children With Sickle Cell Disease Who Received Nitrous Oxide.

Authors:  Michael H Greenwald; Colleen K Gutman; Claudia R Morris
Journal:  Acad Emerg Med       Date:  2019-08-01       Impact factor: 3.451

2.  Urinary dysfunction in transgenic sickle cell mice: model of idiopathic overactive bladder syndrome.

Authors:  Serkan Karakus; Uzoma A Anele; Fábio H Silva; Biljana Musicki; Arthur L Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-19

Review 3.  Testosterone replacement therapy and erectile dysfunction.

Authors:  Ifeanyi C Onyeji; Raul I Clavijo
Journal:  Int J Impot Res       Date:  2022-01-08       Impact factor: 2.896

Review 4.  What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel.

Authors:  S Minhas; A Salonia; M Gül; B Luca; K Dimitropoulos; P Capogrosso; U Milenkovic; A Cocci; R Veeratterapillay; G Hatzichristodoulou; V Modgil; G I Russo; T Tharakan; A Kalkanli; M I Omar; C Bettocchi; J Carvalho; G Corona; T H Jones; A Kadioglu; J I Martinez-Salamanca; E C Serefoglu; P Verze
Journal:  Int J Impot Res       Date:  2022-08-08       Impact factor: 2.408

5.  Resveratrol-nitric oxide donor hybrid effect on priapism in sickle cell and nitric oxide-deficient mouse.

Authors:  Andressa Kely Pinheiro; Dalila Andrade Pereira; Jean Leandro Dos Santos; Fabiano Beraldi Calmasini; Eduardo Costa Alexandre; Leonardo Oliveira Reis; Arthur L Burnett; Fernando Ferreira Costa; Fábio Henrique Silva
Journal:  PLoS One       Date:  2022-06-02       Impact factor: 3.752

Review 6.  Testosterone Deficiency in Sickle Cell Disease: Recognition and Remediation.

Authors:  Biljana Musicki; Arthur L Burnett
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

7.  H2 S catalysed by CBS regulates testosterone synthesis through affecting the sulfhydrylation of PDE.

Authors:  Jing Wang; Jing Wang; Tao Shen; Renyun Hong; Shanshan Tang; Xia Zhao
Journal:  J Cell Mol Med       Date:  2021-03-13       Impact factor: 5.295

8.  Haptoglobin treatment contributes to regulating nitric oxide signal and reduces oxidative stress in the penis: A preventive treatment for priapism in sickle cell disease.

Authors:  Pamela da Silva Pereira; Dalila Andrade Pereira; Fabiano Beraldi Calmasini; Leonardo O Reis; Nathan Brinkman; Arthur L Burnett; Fernando Ferreira Costa; Fábio Henrique Silva
Journal:  Front Physiol       Date:  2022-09-13       Impact factor: 4.755

9.  TSPO ligand FGIN-1-27 controls priapism in sickle cell mice via endogenous testosterone production.

Authors:  Biljana Musicki; Serkan Karakus; Justin D La Favor; Haolin Chen; Fabio H Silva; Mikael Sturny; Barry R Zirkin; Arthur L Burnett
Journal:  J Cell Physiol       Date:  2020-09-24       Impact factor: 6.384

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.